MNPR peer analysis
Monopar Therapeutics (MNPR) against its competitors: price, today's move, 1-year return and market value side by side.
- MNPR's peers: ADCT (ADC Therapeutics), ALXO (ALX Oncology), ATNM (Actinium Pharmaceuticals), BCYC (Bicycle Therapeutics), CMPX (Compass Therapeutics), IMNM (Immunome), IPHA (Innate Pharma), MGNX (MacroGenics).
MNPR and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ADCT ADC Therapeutics | $1.28 | -1.54% | -68.16% | $180.05M |
| ALXO ALX Oncology | $1.06 | 3.92% | -27.89% | $137.03M |
| ATNM Actinium Pharmaceuticals | $1.07 | -0.93% | -21.32% | $33.64M |
| BCYC Bicycle Therapeutics | $2.90 | -4.92% | -53.60% | $202.98M |
| CMPX Compass Therapeutics | $0.67 | -0.87% | -86.27% | $121.13M |
| IMNM Immunome | $15.69 | -5.54% | -11.31% | $1.85B |
| IPHA Innate Pharma | $0.94 | -8.75% | -47.78% | $104.99M |
| MGNX MacroGenics | $1.98 | -0.01% | 39.43% | $126.53M |
| XNCR Xencor | $33.24 | -2.26% | 110.78% | $2.49B |
| ZYME Zymeworks | $26.14 | -2.68% | 15.66% | $1.81B |
| MNPR Monopar Therapeutics | $67.35 | -4.19% | -18.86% | $456.39M |